This fused KDM5A(PHD3):NUP98 found in AML patients directs the “oncoprotein” to H3K4me3 promoter sites, inducing aberrant active transcription leading to AML, as shown in cellular and animal models.20 Here, EGLN3 is linked to acute myeloid leukemia.